MedTrace Logo

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

NCT04417621 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2026-03-12

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma

Conditions

Interventions

DRUG

LXH254

LXH254 will be supplied as tablet for oral use.

DRUG

LTT462

LTT462 will be supplied as hard gelatin capsule for oral use.

DRUG

Trametinib

Trametinib will be supplied as film-coated tablet for oral use

DRUG

Ribociclib

Ribociclib will be supplied in tablets and hard gelatin capsules.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-30
Primary Completion
2027-02-02
Completion
2027-02-02
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Norway
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04417621 on ClinicalTrials.gov